These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11736888)

  • 1. Lung distribution of inhaled drugs.
    Newman SP
    Br J Clin Pharmacol; 2001 Dec; 52(6):716-9. PubMed ID: 11736888
    [No Abstract]   [Full Text] [Related]  

  • 2. Methods to determine lung distribution of inhaled drugs - could gamma scintigraphy be the gold standard?
    Chrystyn H
    Br J Clin Pharmacol; 2000 Jun; 49(6):525-8. PubMed ID: 10848715
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhalation Biopharmaceutics: Progress Towards Comprehending the Fate of Inhaled Medicines.
    Ehrhardt C
    Pharm Res; 2017 Dec; 34(12):2451-2453. PubMed ID: 29147818
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors Affecting Drug Exposure after Inhalation.
    Nováková A; Šíma M; Slanař O
    Prague Med Rep; 2022; 123(3):129-139. PubMed ID: 36107443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaling medicines: delivering drugs to the body through the lungs.
    Patton JS; Byron PR
    Nat Rev Drug Discov; 2007 Jan; 6(1):67-74. PubMed ID: 17195033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current approaches to the discovery of novel inhaled medicines.
    Strong P; Ito K; Murray J; Rapeport G
    Drug Discov Today; 2018 Oct; 23(10):1705-1717. PubMed ID: 29775668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.
    Nahar K; Gupta N; Gauvin R; Absar S; Patel B; Gupta V; Khademhosseini A; Ahsan F
    Eur J Pharm Sci; 2013 Aug; 49(5):805-18. PubMed ID: 23797056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of DMPK by the inhaled route: challenges and approaches.
    Cooper AE; Ferguson D; Grime K
    Curr Drug Metab; 2012 May; 13(4):457-73. PubMed ID: 22299825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs.
    Tronde A; Nordén B; Marchner H; Wendel AK; Lennernäs H; Bengtsson UH
    J Pharm Sci; 2003 Jun; 92(6):1216-33. PubMed ID: 12761811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ and in vivo methods for pulmonary delivery.
    Eljamal M; Nagarajan S; Patton JS
    Pharm Biotechnol; 1996; 8():361-74. PubMed ID: 8791819
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhaled RNA drugs to treat lung diseases: Disease-related cells and nano-bio interactions.
    Zhang M; Lu H; Xie L; Liu X; Cun D; Yang M
    Adv Drug Deliv Rev; 2023 Dec; 203():115144. PubMed ID: 37995899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into pulmonary drug delivery: Mechanism of drug deposition to device characterization and regulatory requirements.
    Rangaraj N; Pailla SR; Sampathi S
    Pulm Pharmacol Ther; 2019 Feb; 54():1-21. PubMed ID: 30447295
    [No Abstract]   [Full Text] [Related]  

  • 13. Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs.
    Barros AS; Costa A; Sarmento B
    Adv Drug Deliv Rev; 2021 Mar; 170():386-395. PubMed ID: 32971227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of microparticles for pulmonary administration.
    Jain H; Bairagi A; Srivastava S; Singh SB; Mehra NK
    Drug Discov Today; 2020 Oct; 25(10):1865-1872. PubMed ID: 32712311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation and prediction of inhaled drug particle accumulation in the lung and its associated toxicity.
    Jones RM; Neef N
    Xenobiotica; 2012 Jan; 42(1):86-93. PubMed ID: 22106935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How can the challenges faced by nanoparticle-based pulmonary drug formulations be overcome.
    Chow SF; Weng J; Xuan B; Wan KY
    Ther Deliv; 2019 Feb; 10(2):87-89. PubMed ID: 30678543
    [No Abstract]   [Full Text] [Related]  

  • 18. Pulmonary absorption - estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis.
    Eriksson J; Sjögren E; Thörn H; Rubin K; Bäckman P; Lennernäs H
    Eur J Pharm Biopharm; 2018 Mar; 124():1-12. PubMed ID: 29191716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of increased nanoparticle absorption by infant lungs: future prospects.
    Garcia-Contreras L; Ibrahim M
    Ther Deliv; 2013 Apr; 4(4):417-20. PubMed ID: 23557280
    [No Abstract]   [Full Text] [Related]  

  • 20. [Aerosol therapy].
    Sheina AN; Shchelkodin PI
    Vopr Kurortol Fizioter Lech Fiz Kult; 1994; (3):32-5. PubMed ID: 7941475
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.